A Keratinocyte-specific Epoxygenase, CYP2B12, Metabolizes Arachidonic Acid with Unusual Selectivity, Producing a Single Major Epoxyeicosatrienoic Acid*

Diane S. KeeneyDagger §, Colin SkinnerDagger , Shozuo Weipar **, Thomas FriedbergDagger Dagger , and Michael R. WatermanDagger

From the Departments of Dagger  Biochemistry & Medicine, § Dermatology, and par  Nephrology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 and the Dagger Dagger  Biomedical Research Centre, Ninewells Hospital and Medical School, Dundee DD1 9SY, United Kingdom

    ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

The CYP monooxygenase, CYP2B12, is the first identified skin-specific cytochrome P450 enzyme. It is characterized by high, constitutive expression in an extrahepatic tissue, the sebaceous glands of cutaneous tissues. It is expressed exclusively in a subset of differentiated keratinocytes called sebocytes, as demonstrated by Northern blot analysis, in situ hybridization, and polymerase chain reaction. The onset of its expression coincides with the morphological appearance of sebaceous glands in the neonatal rat. Recombinant CYP2B12 produced in Escherichia coli epoxidizes arachidonic acid to 11,12- and 8,9-epoxyeicosatrienoic acids (80 and 20% of total metabolites, respectively). The identification of arachidonic acid as a substrate for this skin-specific CYP monooxygenase suggests an endogenous function in keratinocytes in the generation of bioactive lipids and intracellular signaling.

    INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Mammalian CYP monooxygenases (CYP gene superfamily) oxidatively metabolize small, hydrophobic compounds, including steroids, sterols, fatty acids, fat-soluble vitamins, drugs, and toxins (1). These enzymes are expressed in most mammalian tissues, where they function in the biosynthesis or catabolism of endogenous and exogenous substrates. Members of the CYP2B gene subfamily are often called phenobarbital-inducible cytochrome P450 enzymes because phenobarbital treatment results in transcriptional activation of certain hepatic CYP2B genes (2). A typical CYP2B monooxygenase has 16-hydroxylase activity with androgenic steroids, such as testosterone, and is expressed in the liver and organs such as kidney, lung, and testis (2).

CYP2B12 has long been known to be an unusual member of the CYP2B gene subfamily. The gene encoding this enzyme (CYP2B12) was discovered by Atchison and Adesnik (3). Originally called gene 4, it was one of several partial genomic clones that proved the multiplicity of the CYP2B gene subfamily. Gene 4 expression was not detected in the liver or other organs but rather in preputial glands (4), the large, paired sebaceous glands beneath the genital skin in rodents. This finding led Friedberg et al. (4) to isolate and characterize a full-length cDNA corresponding to gene 4 from a preputial gland cDNA library. More than 10 years after its discovery, the novel cytochrome P450 named CYP2B12 is now recognized as the first identified skin-specific cytochrome P450 enzyme.

CYP2B12 has remained enigmatic not only for its restricted tissue-specific expression but also because its substrate was not identified. No activity could be demonstrated with preputial gland microsomes using typical CYP2B substrates, such as testosterone, androstenedione, benzphetamine, and ethoxy-, pentoxy-, and benzoyresorufin (2, 4). Our preliminary investigations of a novel CYP2B in mouse skin1 having sequence homology to rat CYP2B12 renewed interest in this cutaneous P450 enzyme. We report here that CYP2B12 is a gene product unique to sebocytes, a subset of differentiated keratinocytes, and that arachidonate is a substrate for CYP2B12. It is hypothesized that the epoxyeicosatrienoic acids (EETs)2 produced by this enzyme may function in signal transduction pathways essential for establishing or maintaining the differentiated phenotype of keratinocytes in cutaneous tissues.

    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Analysis of CYP2B12 mRNA-- Total RNA was isolated by a modification of the method of Chomczynski and Sacchi as described (5), with the following changes: cutaneous tissues were frozen in liquid nitrogen, pulverized with a mortar and pestle, dissolved in guanidinium thiocyanate solution, and sheared with a 25 gauge needle. For Northern analysis, total RNA was size-fractionated on formaldehyde-containing 1% agarose gels and transferred by capillarity to GeneScreen Plus membranes (DuPont). Membranes were baked at 80 °C and stained with methylene blue to assess RNA integrity. Hybridization was carried out overnight with a 32P-labeled cDNA encoding 3'-untranslated sequences of CYP2B12 (570 bp; GenBank accession no. X63545) or CYP2B15 (260 bp; GenBank accession no. D17349). These fragments were generated by reverse transcription-polymerase chain reaction (RT-PCR) from rat skin RNA using oligonucleotides 1 and 2 for CYP2B12 or oligonucleotides 3 and 4 for CYP2B15 (Table I). Hybridized membranes were washed stringently and exposed to autoradiographic film. For RT-PCR, an RNA PCR kit (Perkin-Elmer) was used according to the manufacturer's instructions, with total RNA as template. Oligonucleotides contained in exons 4 and 9 (Table I, oligonucleotides 5 and 6) were used to determine the tissue distribution of CYP2B12 transcripts. Thus, products amplified from RNA (920 bp) or genomic DNA could be distinguished. The PCR products were size-fractionated on agarose gels and visualized with ethidium bromide. To survey expression of putative CYP epoxygenases in sebaceous tissues by RT-PCR, the following primers (Table I) were used: 1) CYP1A subfamily-specific (oligonucleotides 7 and 8); 2) CYP2B subfamily-specific (oligonucleotides 9 and 10); and 3) CYP3A subfamily-specific (oligonucleotides 11 and 12). Two primer pairs were used in the same reaction to achieve consensus for mammalian CYP2C subfamily members (oligonucleotides 13-16). Finally, two pairs of oligonucleotides were used to detect expression of CYP2E1 (oligonucleotides 17 and 18) and CYP2J3 (oligonucleotides 19 and 20).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Summary of oligonucleotides used in this study (5' right-arrow 3')

In Situ Hybridization-- Sprague-Dawley rats were obtained from Harlan Sprague-Dawley and handled according to protocols approved by Vanderbilt University. Whole skin samples were immersion-fixed for 24 h in 4% buffered paraformaldehyde. Tissue preparation and in situ hybridization were done as described (5). [35S-UTP]cRNAs were produced by in vitro transcription from a 570-bp fragment of CYP2B12 (described above). Specific hybridization was distinguished by comparing silver grain development produced by sense and antisense cRNAs applied to consecutive sections on the same slide.

Expression of CYP2B12 in Escherichia coli-- A CYP2B12 cDNA (4) (pBS2B12) was modified and subcloned into pKK233-2 (Amersham Pharmacia Biotech) to make the expression construct pKK2B12, similar to the method of John et al. (6), who used pKK233-2 successfully to express several CYP2B enzymes in E. coli. Briefly, a 1.6 kb fragment of pBS2B12, containing all but 83 bp of 5'-coding sequence, was isolated by restriction with XbaI, digestion with Klenow fragment of DNA polymerase I to produce a blunt end, and then restriction with NcoI. This fragment was purified and ligated into pKK233-2. Before replacing the missing 83 bp 5'-end of CYP2B12, the native N-terminal sequence MEFGVLL was changed to MALLLAV by PCR mutagenesis as described (6, 7), using oligonucleotides 21 and 22 (Table I). The PCR product containing this N-terminal modification was restricted with NcoI, producing the missing 83-bp fragment, and ligated into pKK2B12 construct above. By DNA sequence analysis, this final pKK2B12 expression construct contained the entire open reading frame of CYP2B12, the MALLLAV N-terminal modification, and 40 bp of untranslated sequence beyond the stop codon. Competent E. coli cells (Topp3 strain; Stratagene) were transformed with pKK2B12. Media and conditions for expression were as described (8). The cultures were harvested after 48-72 h at 30 °C at 200 rpm. Typical yields were >= 500 nmol of P450/liter of culture by whole cell spectral assay. Whole cells or cellular fractions were diluted in 50 mM potassium phosphate buffer containing 20% glycerol to measure CO difference spectra (9). Bacterial membranes solubilized with CHAPS detergent were prepared as described (6) for metabolism studies.

Metabolism Studies-- CYP2B12 activity was assayed as described (10). Briefly, CHAPS-solubilized E. coli membranes were incubated at 30 °C with purified rat NADPH-cytochrome P450 reductase (molar ratio of P450:reductase, 1:5) in the presence of L-alpha -dilauroyl-sn-glycero-3-phosphocholine and a NADPH regenerating system. After 1 min equilibration at 30 °C, [1-14C]arachidonic acid was added (50 µCi/µmol; final concentration, 50-75 µM), and the reaction was initiated with NADPH (final concentration, 1 mM). At various time points, the reaction mixtures were extracted with ethyl ether, and the organic extracts were resolved by reversed phase HPLC with on-line liquid scintillation detection (Radiomatic Flo-One beta -detector; Radiomatic Instruments). For product structural analyses, CYP2B12 was reconstituted in the presence of NADPH and 70 µM [1-14C]arachidonic acid (0.2-0.4 µCi/µmol). Radioactive fractions with retention times corresponding to those of authentic 5,6-, 8,9-, and 11,12-EET were collected, and individual EET regioisomers were resolved by normal phase HPLC as described (10, 11). Purified EET regioisomers were converted to the corresponding pentafluorobenzyl (PFB) esters, and their optical antipodes were resolved by chiral phase HPLC as described (11, 12). Aliquots of purified EET-PFB regioisomers were analyzed by negative ion chemical ionization-gas chromatography-mass spectroscopy (NICI/GC/MS) as described (11). Endogenous EET was measured in freshly isolated rat preputial and clitoral glands. Homogenized tissue was extracted in the presence of triphenylphosphine and analyzed as described by NICI/GC/MS (11). The tissue content of 8,9-, 11,12-, and 14,15-EET was estimated, but 5,6-EET is too labile to be detected (11).

    RESULTS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Skin-specific Expression of CYP2B12-- CYP2B12 is a cutaneous monooxygenase expressed constitutively in rat preputial gland (the tissue source from which a full-length CYP2B12 cDNA was isolated) (4). Among cutaneous tissues, the single most enriched source of CYP2B12 mRNA is the pair of preputial (male) or clitoral (female) (Fig. 1) glands in the rat. These large, paired sebaceous glands in the genital skin are readily dissected free of surrounding cutaneous tissue and subcutaneous fat. As such, they are composed nearly exclusively of keratinocytes at different stages of differentiation. Although CYP2B12 transcripts were detectable in all cutaneous tissues examined, transcript abundance varied. Among samples of full-thickness skin, tail and anogenital skin showed a relatively high level of expression. Lower levels were found in the abdominal skin, ear, and foot pad. For these latter samples, visible bands of the expected molecular size appeared after longer exposure times than that shown in Fig. 1. The differences in hybridization signal intensity among cutaneous tissues appeared to be proportional to the relative size and abundance of sebaceous glands observed morphologically.


View larger version (80K):
[in this window]
[in a new window]
 
Fig. 1.   CYP2B12 transcripts in cutaneous tissues of adult rats detected by Northern blot analysis. RNA was isolated from whole skin (ventral abdominal, foot pad, tail, ear, and anogenital), liver, and isolated clitoral (sebaceous) and adrenal glands. Longer exposure times were required to visualize bands in the lanes showing ventral abdominal skin, ear, and foot pad RNA samples. No signal was detected for liver or adrenal RNAs. The positions of 18S and 28S ribosomal RNAs are indicated.

By Northern blot analysis, CYP2B12 mRNA was undetectable in the liver, lung, kidney, testis, adrenal gland, and intestinal mucosa (4) (Fig. 1). The tissue-specificity of CYP2B12 gene expression was investigated further by the highly sensitive RT-PCR technique. Using total RNA as template, no product of the expected size could be detected in the following noncutaneous tissues of the rat: liver, kidney, lung, heart, adipose, spleen, uterus, ovary, adrenal glands, and tongue (not shown). The positive control, clitoral gland RNA, was amplified only when reverse transcriptase was included in the reaction mixture. These results indicate that CYP2B12 is truly a cutaneous monooxygenase.

Cell-specific Expression of CYP2B12 in Differentiated Keratinocytes-- In situ hybridization was used to identify the cutaneous cell type(s) expressing CYP2B12. CYP2B12 antisense cRNA hybridized specifically to preputial gland acini containing sebaceous keratinocytes. Acini are shown in Fig. 2, A and B, surrounding a central collecting duct, which directs the flow of sebum to the skin surface. At higher magnification (not shown), silver grains localized specifically to sebocytes, the terminally differentiated keratinocytes in this gland, but not to undifferentiated keratinocytes at the periphery of individual acini or any other cutaneous tissue. Reproducible epidermal expression was not observed in situ, although a very low level of expression in epidermal keratinocytes cannot be ruled out. CYP2B12 transcripts also localized to sebocytes in other types of sebaceous glands, for example, the Meibomian glands in the eyelid (not shown), anal glands in anogenital skin (not shown), and sebaceous glands associated with hair follicles. In hair follicles (Fig. 2, C and D), CYP2B12 antisense cRNA localized to sebocytes but not to keratinocytes making up the hair follicle root sheath, epidermis, or other cutaneous structures. During postnatal development, the onset of expression of CYP2B12 coincides with the morphological appearance of well-developed sebaceous glands in both sexes (not shown). These data demonstrate that expression of this cutaneous cytochrome P450 enzyme is restricted to a subset of differentiated keratinocytes found in sebaceous glands.


View larger version (189K):
[in this window]
[in a new window]
 
Fig. 2.   CYP2B12 transcripts localized in situ to the differentiated keratinocytes of sebaceous glands. [35S]cRNA encoding CYP2B12 hybridized with rat anogenital skin. Tissue morphology is shown in brightfield (A and C). Specific hybridization with antisense cRNA is represented by silver grains, which appear white in darkfield (B and D); results for sense cRNA are not shown. A and B, preputial (sebaceous) gland from an 11-day-old male is indicated (arrow) beneath the dermis. C and D, sebaceous glands associated with hair follicles from an adult female. The follicle on the left shows hair fiber and hair root sheath but only the periphery of the associated sebaceous gland (arrow). The follicle on the right shows the major profile of a sebaceous gland (arrow), whereas the associated hair fiber and root sheath are largely beneath the plane of section. Magnification: A and B, × 25; C and D, × 50.

Arachidonic Acid Is a Substrate for CYP2B12-- Differentiated keratinocytes are responsible for producing the unusual lipids found in the epidermal water permeability barrier and sebum (13). Because CYP2B12 is expressed constitutively in lipid-laden sebocytes, it seemed plausible that its endogenous substrate(s) would be lipids. To test this hypothesis, recombinant CYP2B12 was produced in E. coli after its first seven amino acids were replaced with the sequence MALLLAV (7). The DNA sequence of this bacterial expression construct, pKK2B12, was compared with the CYP2B12 cDNA in GenBank (4). Except for the deliberate N-terminal modification, only one difference was found in the nucleotide sequence (ATT right-arrow AGT) that would lead to an amino acid change at residue 476 (Ile right-arrow Ser). At this residue, the sequence of pKK2B12 agreed with that obtained by sequencing RT-PCR products amplified from rat preputial gland RNA.

Reconstituted, recombinant CYP2B12 was active with [14C]arachidonic acid as substrate. Shown in Fig. 3A, metabolism generated, in a NADPH-dependent manner, a major radioactive fraction eluting at 24 min. This fraction had a retention time similar to that of authentic 11,12-EET; radioactivity eluting at 34 min represents unmetabolized substrate. Production of the metabolites contained in this fraction was specific for pKK2B12 transformants because no metabolites were observed with membranes isolated from untransformed E. coli cells (Fig. 3B). CYP2B12 substrate specificity was also demonstrated by its lack of catalytic activity toward the short chain fatty acid laurate (C12:0) (not shown). Metabolites eluting at 24 min (Fig. 3A) were pooled and resolved by normal phase HPLC into two radioactive fractions having the same retention times as authentic 11,12- and 8,9-EET (Fig. 4). These two EETs were the sole reaction products observed, with 11,12- and 8,9-EET accounting for 80 and 20% of total metabolites, respectively. Table II shows the chiral analysis of these products. Both EETs were produced in an enantioselective fashion. The predominant enantiomers generated by CYP2B12 were 11(S),12(R)- and 8(R),9(S)-EET. The stereochemistry of 11,12-EET in Table II is similar to that found endogenously in rat liver (14), further evidence that the function of CYP2B12 is metabolism of arachidonic acid.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 3.   Arachidonic acid metabolites generated by recombinant CYP2B12, resolved by reversed phase HPLC. CHAPS-solubilized membranes were prepared from E. coli transformed with pKK2B12 (A) or untransformed cells (B) and incubated with [14C]arachidonic acid for 20 min at 30 °C. The radioactivity eluting at 34 min represents unmetabolized [14C]arachidonic acid. The arrow in A indicates radioactive metabolites having the same retention time as authentic 11,12-EET standard. No metabolites were observed with membranes isolated from untransformed E. coli cells (B).


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 4.   Resolution of EET regioisomers generated by recombinant CYP2B12. The metabolites eluting at 24 min in Fig. 3A were resolved by normal phase HPLC into two EET regioisomers that eluted with retention times identical to authentic 11,12- and 8,9-EET standards.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Regio- and stereochemical composition of epoxyeicosatrienoic acids produced from [14C]arachidonic acid by recombinant CYP2B12

Structures of the 11,12- and 8,9-EET metabolites were confirmed by NICI/GC/MS. A mass spectral fragmentation pattern for the 11,12-EET-PFB is shown (Fig. 5). Major negative ions were as follows: m/z 319 (loss of the PFB from the molecule), m/z 321 (loss the PFB from the isotopically labeled molecule), and m/z 301 and 303 (loss of PFB, H2O, and oxygen). Similar results were obtained for the purified 8,9-EET produced by CYP2B12 (not shown). The fragmentation patterns are consistent with those of authentic EETs (11). These data demonstrate for the first time that arachidonic acid is a substrate for CYP2B12 and that the regiospecific metabolism by CYP2B12 is unlike most arachidonate (CYP) epoxygenases, which typically produce several EET regioisomers as major products (14).


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 5.   Mass spectral fragmentation pattern for 11,12-EET generated by recombinant CYP2B12. For product structural analysis, CYP2B12 was reconstituted in the presence of NADPH and 70 µM [1-14C]arachidonic acid (0.2-0.4 µCi/µmol). Purified 11,12-EET-PFB was analyzed by NICI/GC/MS. The major anion m/z 319 is diagnostic for loss of PFB from the molecule; that at m/z 321 is derived by loss of PFB from the isotopically labeled molecule.

Production of Endogenous EET in Sebaceous Tissue-- Endogenous EETs were measured in freshly isolated rat preputial and clitoral glands using a quantitative mass spectral assay (11). From 5.7 g of sebaceous tissue, 202 ng of EET were recovered; 49% (98 ng) was 14,15-EET, 25% (51 ng) was 11,12-EET, and 26% (52 ng) was 8,9-EET. These results indicate the presence of another epoxygenase(s) because recombinant CYP2B12 produced 11,12-EET nearly exclusively. Although the fraction of EETs generated by CYP2B12 in sebaceous tissue cannot be determined, one possibility is that CYP2B12 contributes a major fraction of 11,12-EET. However, another epoxygenase(s) must be responsible for generating a major fraction of total EETs.

The identity of other CYP epoxygenases in rat preputial/clitoral glands was explored using RT-PCR and DNA sequencing, whereas the relative abundance of specific transcripts was evaluated by Northern blot analysis or in situ hybridization. CYP1A and CYP3A subfamily-specific oligonucleotides yielded no PCR product. CYP2C subfamily-specific oligonucleotides yielded very faint bands of predicted size, negligible compared with the large amount of product from CYP2B subfamily-specific primers (not shown). CYP2C PCR products were not sequenced because of their low abundance. Sequencing of CYP2B PCR products indicated the presence of CYP2B1/2B2 mRNAs, but the levels in rat skin were too low to be detected by in situ hybridization. In situ hybridization is more sensitive than Northern analysis. In addition to CYP2B12, which is a major transcript (Fig. 1), and low levels of CYP2B1/2B2, CYP2B15 (15) was the third transcript detected in rat sebaceous RNA. CYP2B15 is a major transcript (Fig. 6) that appears to be expressed at levels comparable to CYP2B12, in the same tissues. In situ hybridization studies (not shown) show that CYP2B15 is co-expressed with CYP2B12 in sebocytes.


View larger version (66K):
[in this window]
[in a new window]
 
Fig. 6.   CYP2B15 transcripts in cutaneous tissues of adult rats detected by Northern blot analysis. The membrane represented here was prepared in parallel with that in Fig. 1, using the same RNA samples. These included whole skin (ventral abdominal, foot pad, tail, ear, and anogenital), liver, and isolated clitoral (sebaceous) and adrenal glands. Longer exposure times were required to visualize bands in the lanes showing ventral abdominal skin, ear, and foot pad RNA samples. No signal was detected for liver or adrenal RNAs. The positions of 18S and 28S ribosomal RNAs are indicated.

Although the activity of CYP2B15 is not known, we believe that this enzyme will prove to be an epoxygenase. This hypothesis is based on unpublished data1 suggesting that CYP2B15 is orthologous to murine CYP2B19, a novel keratinocyte-specific CYP2B in mouse skin having epoxygenase activity with arachidonic acid. Hence, we predict that CYP2B12 and CYP2B15 will be the major epoxygenases in rat sebaceous tissues.

Two other CYP2 monooxygenases (CYP2E1 and CYP2J3) having epoxygenase activity (Table III) were detected in preputial/clitoral gland RNA by RT-PCR. Sequence analysis revealed the presence of authentic CYP2E1 and CYP2J3 mRNAs, as well as a novel CYP2J sequence that was 83% identical to both CYP2J3 (16) and CYP2J4 (17) (not shown). By Northern analysis, CYP2E1 and CYP2J3 mRNAs were not detected in clitoral gland RNA after membranes were exposed to film for 2 days (compared with <20 h for Figs. 1 and 6), indicating a low level of constitutive expression (not shown).

                              
View this table:
[in this window]
[in a new window]
 
Table III
Regioselectivity of purified CYP2 family arachidonic acid epoxygenases

In summary, these data demonstrate that CYP2B12 is a major epoxygenase in rat sebaceous tissue, but at least one other major epoxygenase must be present. We predict that the second epoxygenase will prove to be CYP2B15. Furthermore, CYP1A, CYP2C, and CYP3A transcripts are low or undetectable in rat sebaceous glands. CYP2B1/2B2, CYP2E1, and CYP2J3 transcripts are detectable, but constitutive expression is very low compared with that of CYP2B12 and CYP2B15.

    DISCUSSION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

The expression pattern of CYP2B12 is highly unusual compared with other CYP2B genes. First, it shows high, constitutive expression in an extrahepatic tissue. Second, it is expressed in a single cell type: differentiated keratinocytes. As shown by in situ hybridization, it is restricted to a subset of differentiated keratinocytes called sebocytes. As demonstrated by Northern blot analysis, in situ hybridization, and RT-PCR, the singular cell type specificity of this cutaneous cytochrome P450 has few parallels in the CYP gene superfamily. Third, the ontogeny of CYP2B12 gene expression during postnatal development coincides with the morphological appearance of the sebaceous tissues in which the gene is expressed.

The function of CYP2B12 has remained obscure, not only because of its cell type specificity but also because no substrate for CYP2B12 was identified. Preputial gland microsomes showed no enzymatic activity with substrates metabolized by other CYP2B enzymes (4), providing no clues as to the physiological functions of CYP2B12. In situ hybridization studies led us to identify sebocytes as the source of CYP2B12 in skin, providing new insight on potential substrates and endogenous functions. A role in some aspect of cutaneous lipid metabolism seemed plausible because an important function of differentiated keratinocytes in the epidermis and sebaceous glands is the biosynthesis of specialized lipids (13). Cutaneous lipids are essential to prevent excessive transepithelial water loss and are important for thermoregulation in response to stress (13, 18, 19).

The successful expression of CYP2B12 in E. coli allowed the identification of the first known substrate for this enzyme. Recombinant CYP2B12 catalyzes NADPH-dependent epoxidation of arachidonic acid, an important precursor of many lipid mediators (14). Other CYP2B arachidonic acid epoxygenases are known: rabbit lung CYP2B4 (20), a putative CYP2B4 orthologue in guinea pig lung (21), and rat liver CYP2B1 and CYP2B2 (22). Unlike CYP2B12, these CYP2B epoxygenases are expressed in multiple tissues, and their activities are less regioselective. CYP2B12 produces a single major EET regioisomer, mainly 11,12-EET, from arachidonic acid. This degree of regioselectivity during arachidonic acid epoxidation is quite unusual (23) (Table III). An exception is rabbit lung CYP2B4, which generates 5,6-EET as the predominant EET (20). Another distinction is that CYP2B12 catalyzes only epoxidation of arachidonic acid, whereas CYP2B4 (20), CYP2E1 (24), CYP2J3 (16), and CYP2J4 (17), for example, generate omega /omega -1 alcohols or other eicosanoids as major products. Importantly, lauric acid is not a CYP2B12 substrate.

The catalysis of eicosanoid oxidation by CYP2B12 suggests that this enzyme may participate in signal transduction mechanisms in keratinocytes. Although CYP2B12 exhibits a relatively high level of constitutive expression, EET generation may be regulated by cellular phospholipases and arachidonic acid release (14, 23). Another source of EETs might include EETs esterified into cellular glycerophospholipids (25, 26). Although in vivo functions for endogenous EETs produced by CYP2B12 remain to be proven, clues may be obtained from studies of other arachidonic acid epoxygenases. The biological activities of EETs or their hydration products, dihydroxyeicosatrienoic acids, involve changes in membrane permeability to Ca2+, Na+, K+, and H+, as well as stimulation of peptide hormone secretion and vasomodulation (14, 23, 27). In epidermal keratinocyte cultures, increases in extracellular Ca2+ concentrations lead to increases in intracellular Ca2+ concentration and result in keratinocyte differentiation (28, 29). The correlation also exists in mouse epidermis in situ. The greatest concentrations of inter- and intracellular Ca2+ localize cytochemically to the upper epidermal cell layer (30), the stratum granulosum, which contains the most terminally differentiated, nucleated keratinocytes. By analogy, sebocytes are the most terminally differentiated keratinocytes in sebaceous glands. We hypothesize that the CYP2B12-dependent production of 11,12-EET may be involved in establishing the differentiated phenotype or maintaining a differentiated function of keratinocytes in sebaceous tissues.

    ACKNOWLEDGEMENTS

We thank Drs. Yasuna Kobayashi and James Halpert for assistance in expression and purification of CYP2B12 and Dr. Jorge Capdevila for assistance in arachidonic acid metabolism studies and critical interpretation of the data. Support and technical assistance from the Skin Diseases Research Center at Vanderbilt are greatly appreciated, especially the contributions of Drs. Lillian Nanney and Lloyd E. King, Jr., in data interpretation and consultations in cutaneous biology.

    FOOTNOTES

* This work was supported in part by United States Public Health Service Grants P30 AR41943, P30 ES00267, P30 DK26657, IBN-9306922, AR02002 (to D. S.K), and GM37942 (to M. R. W.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Dept. of Biochemistry & Medicine (Dermatology), Vanderbilt University, 607 Light Hall, Nashville, TN 37232-0146. Tel.: 615-322-3318; Fax: 615-322-4349; E-mail: keeneyd{at}ctrvax.vanderbilt.edu.

** Supported by United States Public Health Service Grant DK38226.

1 D. S. Keeney, C. Skinner, and M. R. Waterman, unpublished data.

2 The abbreviations used are: EET, epoxyeicosatrienoic acid; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid; HPLC,high performance liquid chromatography; NICI/GC/MS, negative ion chemical ionization-gas chromatography-mass spectroscopy; PFB, pentafluorobenzyl; PCR, polymerase chain reaction; RT, reverse transcription; bp, base pair(s).

    REFERENCES
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

  1. Nebert, D. W. (1991) Mol. Endocrinol. 5, 1203-1214[Abstract]
  2. Henderson, C. J., and Wolf, C. R. (1992) Prog. Drug Metab. 13, 73-139
  3. Atchison, M., and Adesnik, M. (1986) Proc. Natl. Acad. Sci. U. S. A. 83, 2300-2304[Abstract]
  4. Friedberg, T., Grassow, M. A., Bartlomowicz-Oesch, B., Siegert, P., Arand, M., Adesnik, M., and Oesch, F. (1992) Biochem. J. 287, 775-783[Medline] [Order article via Infotrieve]
  5. Keeney, D. S., Ikeda, Y., Waterman, M. R., and Parker, K. L. (1995) Mol. Endocrinol. 9, 1091-1098[Abstract]
  6. John, G. H., Hasler, J. A., He, Y., and Halpert, J. R. (1994) Arch. Biochem. Biophys. 314, 367-375[CrossRef][Medline] [Order article via Infotrieve]
  7. Barnes, H. J., Arlotto, M. P., and Waterman, M. R. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 5597-5601[Abstract]
  8. Sandu, P., Baba, T., and Guengerich, F. P. (1993) Arch. Biochem. Biophys. 306, 443-450[CrossRef][Medline] [Order article via Infotrieve]
  9. Omura, T., and Sato, R. (1964) J. Biol. Chem. 239, 2379-2385[Free Full Text]
  10. Capdevila, J. H., Falck, J. R., Dishman, E., and Karara, A. (1990) Methods Enzymol. 187, 385-394[Medline] [Order article via Infotrieve]
  11. Capdevila, J. H., Dishman, E., Karara, A., and Falck, J. R. (1991) Methods Enzymol 206, 441-453[Medline] [Order article via Infotrieve]
  12. Hammonds, T. D., Blair, I. A., Falck, J. R., and Capdevila, J. H. (1989) Anal. Biochem. 182, 300-303[Medline] [Order article via Infotrieve]
  13. Nicolaides, N. (1974) Science 186, 19-26[Medline] [Order article via Infotrieve]
  14. Capdevila, J. H., Zeldin, D., Karara, A., and Falck, J. R. (1996) Adv. Mol. Cell. Biol. 14, 317-339
  15. Nakayama, K., Suwa, Y., Mizukami, Y., Sogawa, K., and Fujii-Kuriyama, Y. (1993) Gene 136, 333-336[Medline] [Order article via Infotrieve]
  16. Wu, S., Chen, W., Murphy, E., Gabel, S., Tomer, K. B., Foley, J., Steenbergen, C., Falck, J. R., Moomaw, C. R., and Zeldin, D. C. (1997) J. Biol. Chem. 272, 12551-12559[Abstract/Free Full Text]
  17. Zhang, Q.-Y., Ding, X., and Kaminsky, L. S. (1997) Arch. Biochem. Biophys. 340, 270-278[CrossRef][Medline] [Order article via Infotrieve]
  18. Wheatley, V. R. (1986) Physiol. Pathophysiol. Skin 9, 2705-2721
  19. Chen, W., Kelly, M. A., Opitz-Araya, X., Thomas, R. E., Low, M. J., and Cone, R. D. (1997) Cell 91, 789-798[Medline] [Order article via Infotrieve]
  20. Zeldin, D. C., Plitman, J. D., Kobayashi, J., Miller, R. F., Snapper, J. R., Falck, J. R., Szarek, J. L., Philpot, R. M., and Capdevila, J. H. (1995) J. Clin. Invest. 95, 2150-2160[Medline] [Order article via Infotrieve]
  21. Knickle, L. C., and Bend, J. R. (1994) Mol. Pharmacol. 45, 1273-1280[Abstract]
  22. Capdevila, J. H., Karara, A., Waxman, D. J., Martin, M. V., Falck, J. R., and Guengerich, F. P. (1990) J. Biol. Chem. 265, 10865-10871[Abstract/Free Full Text]
  23. Capdevila, J. H., Zeldin, D., Makita, K., Karara, A., and Falck, J. R. (1995) in Cytochrome P450: Structure, Mechanism and Biochemistry (Ortiz de Montellano, P. R., ed), pp. 443-471, Plenum Press, New York
  24. Laethem, R. M., Balazy, M., Falck, J. R., Laethem, C. L., and Koop, D. R. (1993) J. Biol. Chem. 268, 12912-12918[Abstract/Free Full Text]
  25. Zhu, Y., Schieber, E. B., McGiff, J. C., and Balazy, M. (1995) Hypertension 25, 854-859[Abstract/Free Full Text]
  26. Karara, A., Dishman, E., Falck, J. R., and Capdevila, J. H. (1991) J. Biol. Chem. 266, 7561-7569[Abstract/Free Full Text]
  27. Fitzpatrick, F. A., and Murphy, R. C. (1989) Pharmacol. Rev. 40, 229-241[Medline] [Order article via Infotrieve]
  28. Yuspa, S. H., Kilkenny, A. E., Steinert, P. M., and Roop, D. R. (1989) J. Cell Biol. 109, 1207-1217[Abstract]
  29. Hennings, H., Kruszewski, F. H., Yuspa, S. H., and Tucker, R. W. (1989) Carcinogenesis 10, 777-780[Abstract]
  30. Menon, G. K., Grayson, S., and Elias, P. M. (1985) J. Invest. Dermatol. 84, 508-512[Abstract]
  31. Laethem, R. M., and Koop, D. R. (1992) Mol. Pharmacol. 42, 958-963[Abstract]
  32. Daikh, B. E., Lasker, J. M., Raucy, J. L., and Koop, D. R. (1994) J. Pharmacol. Exp. Therapeut. 271, 1427-1433[Abstract]
  33. Zeldin, D. C., DuBois, R. N., Falck, J. R., and Capdevila, J. H. (1995) Arch. Biochem. Biophys. 322, 76-86[CrossRef][Medline] [Order article via Infotrieve]
  34. Imaoka, S., Wedlund, P. J., Ogawa, H., Kimura, S., Gonzalez, F. J., and Kim, H.-Y. (1993) J. Pharmacol. Exp. Ther. 267, 1012-1016[Abstract]
  35. Karara, A., Makita, K., Jacobson, H. R., Falck, J. R., Guengerich, F. P., DuBois, R. N., and Capdevila, J. H. (1993) J. Biol. Chem. 268, 13565-13570[Abstract/Free Full Text]
  36. Wu, S., Moomaw, C. R., Tomer, K. B., Falck, J. R., and Zeldin, D. C. (1996) J. Biol. Chem. 271, 3460-3468[Abstract/Free Full Text]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.